Compare LOB & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOB | NTLA |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2014 | 2016 |
| Metric | LOB | NTLA |
|---|---|---|
| Price | $37.86 | $12.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 23 |
| Target Price | ★ $43.00 | $20.02 |
| AVG Volume (30 Days) | 159.7K | ★ 3.4M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | ★ 31.95 | 27.43 |
| EPS | ★ 1.35 | N/A |
| Revenue | N/A | ★ $67,671,000.00 |
| Revenue This Year | $35.52 | N/A |
| Revenue Next Year | $16.03 | $62.75 |
| P/E Ratio | $28.05 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $29.36 | $7.95 |
| 52 Week High | $44.53 | $28.24 |
| Indicator | LOB | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 29.82 | 55.35 |
| Support Level | $37.47 | $11.51 |
| Resistance Level | $38.34 | $13.88 |
| Average True Range (ATR) | 0.78 | 0.52 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 8.55 | 86.68 |
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.